FORM 3A - Director/Chief Executive Notice - Interests in Shares of Listed Corporation
 
Form Serial Number: DA20260613E00015
1. Date of relevant event: 11/06/2026
(dd/mm/yyyy)
2. Date when director became aware of the relevant event/ interest in the shares (if later):
(dd/mm/yyyy)
3. Stock code: 06160
4. Name of listed corporation: BeOne Medicines Ltd. 
5. Class of shares: Ordinary Shares 
6. Number of issued shares in class: 1,541,583,805
7. Name of director (English) as printed on HKID Card/Passport:
(Surname) Baker
(Other names) Felix James
10. Name of director (Chinese):  
11. Chinese Character Code as printed on HKID Card:
 
24. Details of relevant event:
  Brief description of relevant event Capacity in which shares were/are held Number of shares bought/sold or involved Currency of transaction On Exchange Off Exchange
Before relevant event After relevant event Highest price (per share) Average price (per share) Average consideration (per share) Consideration code
Long position 
11033The number of shares in which you are interested has increased because:
you became the holder of, wrote or issued equity derivatives under which (choose one):
you have a right to receive from another person an amount if the price of the underlying shares is above a certain level
 
 
2101Beneficial owner
 		 18,980  USD       
3104Services
 
Short position 
 
 
 		            
 
25. Total shares in listed corporation immediately before the relevant event:
 Total number of sharesPercentage figure (%)
Long position115,912,8147.52
 
26. Total shares in listed corporation immediately after the relevant event:
 Total number of sharesPercentage figure (%)
Long position115,931,7947.52
 
27. Capacity in which interests disclosed in Box 26 are held:
Code describing capacityNumber of shares
2201Interest of corporation controlled by you
Long position114,532,252
2106Person having a security interest in shares
Long position1,069,419
2101Beneficial owner
Long position154,415
2301Trustee
Long position175,708
 
28. Further information in derivative interests in listed corporation :
Derivatives code Exercise period (dd/mm/yyyy) Consideration - if derivatives granted by listed corporation Number of shares
  BeginsEndsCurrencyPrice for grantCurrencyExercise priceCurrencyPrice on assignment 
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
11/06/2026 USD0USD0.000USD20.02018,980
Long position
4102Listed derivatives - Cash settled
  USD0USD0.000USD0.000114,843,339
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
19/04/201711/12/2026USD0USD2.840USD2.840399,984
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
06/06/201805/06/2028USD0USD16.150USD16.15034,866
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
06/06/2018 USD0USD0.000USD16.15018,564
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
05/06/201904/06/2029USD0USD9.230USD9.230129,220
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
17/06/202111/06/2029USD0USD13.420USD13.42090,766
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
17/06/202211/06/2029USD0USD26.530USD26.53034,996
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
17/06/2022 USD0USD0.000USD26.53015,600
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
22/06/202311/06/2029USD0USD11.980USD11.98069,290
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
22/06/2023 USD0USD0.000USD11.98033,384
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
15/06/202411/06/2029USD0USD16.410USD16.41053,950
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
15/06/2024 USD0USD0.000USD16.41025,844
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
21/05/202511/06/2029USD0USD12.230USD12.23068,302
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
21/05/2025 USD0USD0.000USD12.23032,682
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
21/05/202611/06/2029USD0USD18.190USD18.19045,500
Long position
4108Unlisted derivatives - Other (you must describe the category of derivatives in the Supplementary Information box)
21/05/2026 USD0USD0.000USD18.19016,471
 
29. Further information in relation to interests of children under 18 and/or spouse:
Child/SpouseName of child/spouseNumber of shares
 
 
30. Further information in relation to interests of corporations controlled by Director:
Name of controlled corporationAddress and place of incorporationName of controlling person% controlDirect interest (Y/N)Number of shares
Baker Brothers Life Sciences Capital (GP), LLC860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USAFelix Baker100.00N
Long position104,889,368
Baker Brothers Life Sciences Capital, L.P.860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USABaker Brothers Life Sciences Capital (GP), LLC100.00N
Long position104,889,368
Baker Brothers Life Sciences, L.P.860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USABaker Brothers Life Sciences Capital, L.P.100.00Y
Long position104,889,368
Baker Biotech Capital (GP), LLC860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USAFelix Baker100.00N
Long position9,498,367
Baker Biotech Capital L.P.860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USABaker Biotech Capital (GP), LLC100.00N
Long position9,498,367
667, L.P.860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USABaker Biotech Capital L.P.100.00Y
Long position9,498,367
FBB3 LLC860 Washington Street, 3rd Floor, New York, NY 10014. Place of incorporation: Delaware USAFelix Baker100.00Y
Long position144,517
 
31. Further information in relation to interests held by Director jointly with another person:
Name of joint shareholderAddressNumber of shares
 
 
32. Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust:
Names of TrustAddressStatus codeNumber of shares
(private)Addresses of individuals are not displayed.
5101Trustee of a trust
Long position175,708
 
33. Further information from a party to an agreement under Section 317 (Please see Notes for further information required):
Names of other partiesAddressNumber of shares
 
Total number of shares in which a director is interested under sections 317 and 318
 
34. Supplementary information: Felix Baker, managing member of Baker Bros. Advisors (GP) LLC, general partner of Baker Bros. Advisors LP ("BBA"), was appointed director of BeOne Medicines, Ltd. on June 11, 2026 and received restricted stock ("RSU") (18,980 granted on Box 1 date). BBA manages securities held by 667, L.P. and Baker Brothers Life Sciences, L.P. Per BBA policy, Mr. Baker has no pecuniary interest in the RSU. Unlisted derivatives include stock options and RSU held by BBA employees; refer to Jan 11, 2019 filing.
35. Log/Serial Number of the previous form:
36. Number of concert party document(s) under section 317 attached/uploaded:
Date of filing this Form 3A: 13/06/2026
(dd/mm/yyyy)